Quick Facts
  • Primary Location:
    Duke Cancer Center
  • Expertise:
    Stereotactic Body Radiotherapy
    Clinical Trials
  • Speciality:
    Radiation Oncology
  • Gender:
    Male
  • Language:
    English
  • Med School:
    University of Colorado School of Medicine

Get to Know Dr. Christopher R. Kelsey

Radiation oncologist Dr. Christopher Kelsey is part of the multidisciplinary team of doctors caring for patients with malignant mesothelioma at the Duke Cancer Center.

As a professor of oncology at Duke University, Kelsey has a keen research interest in genetic determinants of radiation sensitivity and personalized medicine.

Kelsey’s goal with each patient is finding the optimal levels of treatment to produce the best possible tumor control, while decreasing the risk of long-term side effects.

He is currently involved in several studies, including one involving predictors of local recurrence after surgery for lung cancer.

Kelsey works closely with other specialists, such as oncologists and surgeons, throughout the multidisciplinary approach to treatment. He is known for building close relationships with patients and their families, along with an ability to win their confidence.

“For me, it is rewarding to work with individuals who express so much courage in overcoming a difficult diagnosis,” he said. “I find great satisfaction working with cancer patients to help allay their fears and provide the best possible care.”

Contact Christopher R. Kelsey

Specialties of Dr. Christopher R. Kelsey

  • Radiation therapy
  • Clinical trials
  • Stereotactic body radiotherapy
  • Lung cancer
  • Pleural mesothelioma                                                              
  • Hodgkin’s lymphoma
  • Multiple myeloma

Dr. Christopher R. Kelsey’s Experience and Medical Education

  • Duke University Cancer Center
  • Associate Professor of Radiation Oncology, Duke University Cancer Institute
  • Duke University Medical School (Residency)
  • University of Colorado Medical School (M.D.)

Awards and Certifications

  • American Board of Radiology
  • Algernon Sydney Sullivan Award, Duke University

Publications of Dr. Christopher Kelsey

  • Raman, V. et al. (2021, January 7). Tumor Size, Histology, and Survival after Stereotactic Ablative Radiotherapy and Sublobar Resection in Node-Negative Non-Small Cell Lung Cancer. Annals of Surgery.
  • Fairchild, A. et al. (2020, December 30). Primary Mediastinal (Thymic) Large B-Cell Lymphoma: Fidelity of Diagnosis Using WHO Criteria. Clinical Lymphoma, Myeloma & Leukemia.
  • Jacobs, C. et al. (2020, May). Definitive Radiotherapy for Inoperable Stage IIB Non-Small Cell Lung Cancer: Patterns of Care and Comparative Effectiveness. Clinical Lung Cancer.
  • Kelsey, C.R. & Prosnitz, L.R. (2014, June). Radiation Oncology Consultation for Hematologic Malignancies. Cancer Consult: Expertise for Clinical Practice.

Lab technician using a microscope in a lab
COVID-19 and Mesothelioma Presentation
United States one-hundred-dollar bills
Access More than $32 Billion in Trust Funds
Technician documenting notes in a lab
Find Active Mesothelioma Clinical Trials

  •  
  •  
  •  
Tell us what you think
Did this article help you?
How did this article help you?
What about this article isn’t helpful for you?
Did this article help you?

Thank you for your feedback. Would you like to speak with a Patient Advocate?